ArticleRenal failure2025
The association of iron status on clinical outcomes in peritoneal dialysis: a retrospective study over 10 years.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron deficiency and overload are common in kidney disease. Although the relation between iron status and clinical outcome is well reported in hemodialysis, there are few publications in peritoneal dialysis (PD). We investigated the association between iron status and outcomes of new PD patients. We reviewed 1,804 new adult PD patients between 2011 and 2020. Their baseline status was classified into reference iron status (RIS), absolute iron deficiency (AID), low iron storage (LIS), functional iron deficiency (FID), and high iron status (HIS) according to the transferrin saturation and serum ferritin level. After a median follow-up of 35.2 months, outcome measures, including patient survival, technique survival, peritonitis-free survival, number of hospital admission, and length of hospitalization, were analyzed. FID and HIS were found in 18.8% and 57.5% patients, respectively. The 2-year patient survival for RIS, AID, LIS, FID, and HIS groups were 87.4%, 90.2%, 94.7%, 82.0%, and 83.5%, respectively (log-rank test,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.